GEOGRAPHIC ATROPHY
Clinical trials for GEOGRAPHIC ATROPHY explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection aims to slow vision loss from Age-Related macular degeneration
Disease control OngoingThis study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gene therapy trial aims to halt blindness in dry AMD
Disease control OngoingThis study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug aims to slow vision loss in Age-Related blindness
Disease control OngoingThis study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Bionic eye implant aims to bring back sight in advanced macular degeneration
Disease control OngoingThis study tests a device called the PRIMA System, which includes an implant placed under the retina and a special visual processor worn by the patient. The goal is to help people with advanced dry age-related macular degeneration (geographic atrophy) regain some central vision. …
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Syfovre safety check: Real-World study tracks eye drug in 300 patients
Disease control OngoingThis study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …
Matched conditions: GEOGRAPHIC ATROPHY
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Telescope eye implant study for AMD withdrawn before it began
Disease control TerminatedThis study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New eye drug takes on leading cause of blindness in the elderly
Disease control OngoingThis study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThis study tests whether monthly eye injections of ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection. The main goa…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Sound-Guided gaze: new device aims to sharpen eye imaging for the visually impaired
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device that uses real-time sound feedback to help people with vision loss fix their gaze on a target. Participants hear sounds that guide their eyes back to center when they drift. The goal is to improve the quality of eye imaging by reducing blur from eye move…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New eye imaging could reveal hidden clues to vision loss
Knowledge-focused ENROLLING_BY_INVITATIONThis study explores whether combining three eye-imaging techniques can reveal how structural damage in the retina relates to vision loss in people with geographic atrophy, a form of age-related macular degeneration. Researchers will use OCT scans, ultra-high-resolution AOSLO imag…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC